| BioBuzz has been connecting the life science workforce since 2009. We’ve built an expansive community in the Mid-Atlantic with a national readership that spans from Massachusettes to Florida, and New York to California. For our next chapter, we’re building a proprietary talent logistics model to help employers source and hire life science talent. Learn more. |
VerImmune Inc., the Washington D.C. based biotechnology company, has just secured $4.5 million in the first closing of its Pre-Series A financing, bringing it one step closer to its groundbreaking mission: to revolutionize cancer immunotherapy. The company’s main aim is to transform the lives of cancer patients by creating safe, effective, and long-lasting medicines that can leverage our immune system to battle many types of cancer.
Imagine a world where innovative treatments can directly target cancer cells with unparalleled precision—this is the promise of VerImmune’s unique Virus-Inspired Particle (ViP™) platform technology. With this new funding, VerImmune will accelerate the development of its revolutionary approach, potentially opening doors not only for cancer treatment but also for tackling other devastating diseases. This advancement could be the beacon of hope we’ve been waiting for, transforming lives and redefining the future of medical solutions.
The Potential of ViP™ Technology in Cancer Immunotherapy
VerImmune’s ViP™ technology offers a promising new approach to cancer treatment by harnessing the body’s immune system. By utilizing the immune “memories” formed from previous infections or vaccinations, ViP™ cleverly enables the body to recognize and target cancer cells without creating a new response from scratch. This clever approach of using past immune responses to fight new tumors is known as Anti-tumor Immune Redirection (AIR).
Inspired by the natural behavior of viruses, the ViP™ platform is designed to mimic how viruses operate within the body. Viruses are efficient vectors that can easily enter and exit cells, triggering an immune response. VerImmune’s ViP™ particles act like harmless viruses, infiltrating cancer cells and deceiving the immune system into recognizing these cells as viral invaders. This trick prompts the immune system to mount a robust response against the cancer cells, destroying them.
One of the standout candidates emerging from this platform is VERI-101, which employs the AIR approach to guide immune cells to cancerous targets. VERI-101 harnesses the body’s immunological memory against cytomegalovirus to direct the immune response towards tumors. This method holds particular promise for patients whose cancers have become resistant to existing therapies. Unlike most current treatments that target specific cancer types, VERI-101 has the potential to combat various tumors due to its mechanism of action not relying on the unique biology of any single cancer type.
Overcoming Resistance and Enhancing Treatment Options
VerImmune’s ViP™ technology also offers hope to patients who have not responded to PD-1/PD-L1 therapies. PD-1/PD-L1 therapy is a form of cancer immunotherapy that involves blocking the interaction between PD-1 on T-cells and PD-L1 on cells, which some cancer cells exploit to avoid immune attack. While this therapy can be effective, it does not work for everyone. VerImmune’s approach can reduce patients’ dependence on PD-1/PD-L1 therapy and function as a standalone treatment or in conjunction with other therapies.
Another innovative aspect of ViP™ technology is its personalization. By relying on the patient’s existing immune memory, doctors can identify individuals who will benefit most from the therapy. This means some patients might only need to reactivate an immune response that is already present, without requiring additional treatments.
Endorsements and Future Prospects
The potential of VerImmune’s ViP™ platform and VERI-101 has attracted strategic partners and investors. Dr. Che Hsu praises the ViP™ technology.
“We are very attracted by and delighted to invest in VerImmune’s Virus-inspired Particle (ViP), which is both non-viral and well differentiated. It is technically superior to other virus-like particle modalities in addressing well-recognized existing challenges. We are confident in its future success.”
Similarly, Haolin Sung, MBA Partner at Proxima Ventures, states “We are extremely pleased to continue our support for VerImmune. The company’s ViP™ technology offers a new class of ‘virally inspired’ proteins that can function as a non-viral delivery system, systematically and efficiently manipulating proteins beyond traditional rules.”
VerImmune’s advancements could be a crucial step forward, offering hope for more effective treatment and a brighter future in the fight against this disease.
